ALFERON N Rx
Generic Name and Formulations:
Interferon alfa-n3 (human leukocyte derived) 5million IU/mL; inj; contains albumin (human).
Hemispherx Biopharma, Inc.
Indications for ALFERON N:
Refractory genital warts.
≥18yrs: 0.05mL (250,000 IU) injected into the base of each wart twice weekly; max 8 wks. Max dose per session: 0.5mL (2.5million IU). Wait 3 months before retreatment unless warts enlarge or new warts develop.
<18 yrs: not recommended.
Mouse immunoglobulin, egg protein, or neomycin allergy.
Cardiovascular or severe pulmonary disease. Coagulation or seizure disorders. Severe myelosuppression. Use effective contraception during treatment. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended.
Endocrinology Advisor Articles
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD
- Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
- Romosozumab: Effective in Men With Osteoporosis
- Guidelines for Management of Hypothalamic-Pituitary, Growth Disorders in Childhood Cancer Survivors
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- NT-proBNP May Predict Cardiovascular Outcomes in Type 2 Diabetes
- Placebo Effect of Various Female Sexual Dysfunction Drug Txs Assessed
- Link Between Oral Diabetes Medications and Bullous Pemphigoid
- Calcium Channel Blocker May Benefit Patients With Type 1 Diabetes
- β-Cell Function in Youth With Impaired Glucose Tolerance, T2D